AHRQ Comparative Effectiveness Funding Doubled In 2008 Budget Bills
Executive Summary
Funding for medical product comparative effectiveness research within the HHS Agency for Healthcare Research and Quality would increase to $30 million in fiscal year 2008 appropriations legislation pending in both the House and Senate
You may also be interested in...
New Antidiabetics Need Head-To-Head Trials With Existing Regimens – AHRQ
New insulin therapies need to be compared to traditional insulin therapies in studies with regimens that resemble usual clinical practice, the Agency for Healthcare Research and Quality says
New Antidiabetics Need Head-To-Head Trials With Existing Regimens – AHRQ
New insulin therapies need to be compared to traditional insulin therapies in studies with regimens that resemble usual clinical practice, the Agency for Healthcare Research and Quality says
Senate passes HHS funding bill
The Senate Oct. 23 passed the HHS and labor appropriations bill by 75-19, an amended version of the House bill (H.R. 3043), which passed in July by a 276-140 vote. The bills propose increasing funding for the HHS Agency for Healthcare Research and Quality to $329.6 million for FY 2008, a $10.6 million increase from FY 2007. Within AHRQ's funding is an increase for comparative effectiveness research from $15 million in FY 2007 to $30 million in FY 2008 (1"The Pink Sheet" July 16, 2007, p. 23). Congress is authorized to allocate up to $50 million for comparative effectiveness research under the Medicare Modernization Act...